184 related articles for article (PubMed ID: 7707278)
21. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
Levy GD; Rapaport MH
Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of hyoscine hydrobromide in reducing side-effects induced during immersion in virtual reality.
Regan EC; Ramsey AD
Aviat Space Environ Med; 1996 Mar; 67(3):222-6. PubMed ID: 8775399
[TBL] [Abstract][Full Text] [Related]
23. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
Noy S; Shapira S; Zilbiger A; Ribak J
Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
[TBL] [Abstract][Full Text] [Related]
24. Vestibular evoked myogenic potentials and motion sickness medications.
Tal D; Shemy S; Kaminski-Graif G; Wiener G; Hershkovitz D
Clin Neurophysiol; 2016 Jun; 127(6):2350-4. PubMed ID: 27178852
[TBL] [Abstract][Full Text] [Related]
25. Effect of the anti-motion-sickness medication cinnarizine on central nervous system oxygen toxicity.
Arieli R; Shupak A; Shachal B; Shenedrey A; Ertracht O; Rashkovan G
Undersea Hyperb Med; 1999; 26(2):105-9. PubMed ID: 10372430
[TBL] [Abstract][Full Text] [Related]
26. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
[TBL] [Abstract][Full Text] [Related]
27. Cinnarizine in the prophylaxis of car sickness in children.
Macnair AL
Curr Med Res Opin; 1983; 8(7):451-5. PubMed ID: 6627971
[TBL] [Abstract][Full Text] [Related]
28. Time-course of effects of oral cinnarizine and hyoscine on task performance.
Golding JF; Strong R; Pethybridge RJ
J Psychopharmacol; 1989 Jan; 3(4):187-97. PubMed ID: 22282908
[TBL] [Abstract][Full Text] [Related]
29. Central effects of cinnarizine: restricted use in aircrew.
Nicholson AN; Stone BM; Turner C; Mills SL
Aviat Space Environ Med; 2002 Jun; 73(6):570-4. PubMed ID: 12056673
[TBL] [Abstract][Full Text] [Related]
30. Experimental assessment of selected antimotion drugs.
Matsnev EI; Bodo D
Aviat Space Environ Med; 1984 Apr; 55(4):281-6. PubMed ID: 6732678
[TBL] [Abstract][Full Text] [Related]
31. Seasickness as a self-fulfilling prophecy: raising self-efficacy to boost performance at sea.
Eden D; Zuk Y
J Appl Psychol; 1995 Oct; 80(5):628-35. PubMed ID: 7592232
[TBL] [Abstract][Full Text] [Related]
32. [Use of reflexotherapy in the prevention and treatment of motion sickness].
Ivanov AL; Snitko VM
Voen Med Zh; 1985 Aug; (8):56-7. PubMed ID: 4060629
[No Abstract] [Full Text] [Related]
33. Airsickness prevention in helicopter passengers.
Estrada A; LeDuc PA; Curry IP; Phelps SE; Fuller DR
Aviat Space Environ Med; 2007 Apr; 78(4):408-13. PubMed ID: 17484344
[TBL] [Abstract][Full Text] [Related]
34. Motion illness.
Hervey GR
Trans Med Soc Lond; 1984-1985; 101():14-20. PubMed ID: 6152833
[No Abstract] [Full Text] [Related]
35. Seasickness in totally-enclosed motor-propelled survival craft: remedial measures.
Landolt JP; Monaco C
Aviat Space Environ Med; 1992 Mar; 63(3):219-25. PubMed ID: 1567325
[TBL] [Abstract][Full Text] [Related]
36. Cinnarizine in migraine prophylaxis: efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial.
Rossi P; Fiermonte G; Pierelli F
Funct Neurol; 2003; 18(3):155-9. PubMed ID: 14703897
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of the effectiveness of drugs for prevention of motion sickness].
Galle RR; Gusakova GA; Sabaev VV; Galle NN
Kosm Biol Aviakosm Med; 1988; 22(4):90-4. PubMed ID: 3066982
[No Abstract] [Full Text] [Related]
38. Control of simulator sickness in an AH-64 aviator.
Kroll JD
Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677
[TBL] [Abstract][Full Text] [Related]
39. Side-effects of 1-hyoscine and cyclizine studied by objective tests.
Brand JJ; Colquhoun WP; Perry WL
Aerosp Med; 1968 Sep; 39(9):999-1002. PubMed ID: 4876723
[No Abstract] [Full Text] [Related]
40. The Vestibular Time Constant and Clinical Response to Antimotion Sickness Medication.
Lagami D; Shupak A; Jamison A; Tal D
Ear Hear; 2023 Nov-Dec 01; 44(6):1404-1409. PubMed ID: 37221635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
